From Start to Finish: How Agilent Can Support Better Decisions in IVT mRNA-Based Biopharmaceutical Analysis
Development and production of IVT mRNA vaccines require measurements of Critical Quality Attributes (CQAs), such as identity, purity, quality, and quantity. Orthogonal methods developed for such purposes are outlined in the USP guidelines for mRNA vaccines.
Agilent Technologies provides many analytical solutions that are used by leading pharmaceutical companies in early-stage drug development through production quality control (QC) and final product release. These systems help users save time and money with optimized workflows, streamlined processes, and fast time-to-results.
Whitney Pike, M.Sc, Application Scientist and Dr. Sonja Schneider, Manager, Application Development, Agilent Technologies, will discuss how automated electrophoresis and LC/MS systems solutions from Agilent provide reliable insights for IVT mRNA workflows at many steps, from QC of the initial plasmid DNA, throughout the IVT process, to the finished mRNA drug product.
Key learning objectives
- Explore QC throughout the entire IVT mRNA workflow, including data from various nucleic acids and LNP analyses
- Discover how Agilent instruments/technologies, such as the Fragment Analyzer and LC/MS systems, can be used for different CQAs
- Learn how Agilent is working together with its partners to provide reliable insights for all aspects of the IVT mRNA workflow
Who should attend?
- Researchers, lab managers, lab directors, QA/QC managers performing IVT mRNA analysis in biotherapeutics research and production
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
For Research Use Only. Not for use in diagnostic procedures. PR7001-2498
Speakers
Whitney joined Agilent in 2016 and is an Application Scientist with a focus on the Agilent Automated Electrophoresis instruments. She played a pivotal role in the release of the Femto Pulse system as a scientist on the product development team. She completed her master’s degree in biology, with an emphasis on cellular, molecular, and developmental biology, before working at a core facility, responsible for performing next-generation sequencing studies.
Dr. Sonja Schneider completed her diploma degree in biology and her PhD in biochemistry before joining Agilent in 2011 as an Application Scientist for biopharma applications. She progressed into her current role as Manager, of the Application Development Team in 2016, whilst simultaneously working in the laboratory on up-to-date biopharma applications.
Moderator
